WO1999055726A1 - Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline - Google Patents

Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline Download PDF

Info

Publication number
WO1999055726A1
WO1999055726A1 PCT/EP1999/002690 EP9902690W WO9955726A1 WO 1999055726 A1 WO1999055726 A1 WO 1999055726A1 EP 9902690 W EP9902690 W EP 9902690W WO 9955726 A1 WO9955726 A1 WO 9955726A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
alkyl
lower alkyl
aryl
substituted
Prior art date
Application number
PCT/EP1999/002690
Other languages
English (en)
Inventor
Stéphane De Lombaert
Cynthia Anne Fink
Fariborz Firooznia
Denton Wade Hoyer
Arco Yingcheu Jeng
Original Assignee
Novartis Ag
Novartis-Erfindungen Verwaltungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000545884A priority Critical patent/JP4350306B2/ja
Priority to KR1020007011725A priority patent/KR20010034816A/ko
Priority to EP99920729A priority patent/EP1073674A1/fr
Priority to CA002323691A priority patent/CA2323691A1/fr
Priority to IL13824699A priority patent/IL138246A0/xx
Priority to SK1581-2000A priority patent/SK15812000A3/sk
Priority to BR9909805-9A priority patent/BR9909805A/pt
Priority to PL99343594A priority patent/PL343594A1/xx
Application filed by Novartis Ag, Novartis-Erfindungen Verwaltungsgesellschaft Mbh filed Critical Novartis Ag
Priority to HU0101640A priority patent/HUP0101640A3/hu
Priority to AU38199/99A priority patent/AU3819999A/en
Publication of WO1999055726A1 publication Critical patent/WO1999055726A1/fr
Priority to US09/690,060 priority patent/US6423727B1/en
Priority to NO20005293A priority patent/NO20005293L/no
Priority to US10/080,798 priority patent/US6613782B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the compounds of formula I below which have been discovered to be useful as endothelin-converting enzyme (ECE) inhibitors in mammals.
  • the thiol derivatives described herein inhibit the formation of endothelin, reduce the plasma and tissue levels of endothelin and inhibit the biological effects of endothelin activity in mammals.
  • the present invention provides a method of inhibiting ECE and a method of treating and/or preventing endothelin dependent conditions and diseases, e.g. cardio- and cerebro- vascular disorders such as essential hypertension, vasoconstriction, congestive heart failure, pulmonary hypertension, cerebral ischemia (stroke), subarachnoid hemorrhage, traumatic brain injury, acute and chronic renal failure, atherosclerosis, cerebral vasospasm, arterial hypertrophy, restenosis, Raynaud's disease, myocardial infarction, obesity; also respiratory disorders such as bronchial asthma; gastrointestinal disorders such as inflammatory bowel disease, pancreatitis, emesis; also prostate hyperplasia, migraine, diabetes mellitus (diabetic nephropathy), preeclampsia, glaucoma and transplantation rejection, such as in aorta or solid organ transplantation in either allo- or xeno- transpiantation; as well as erectile dysfunction;
  • the present invention is also directed to ECE inhibiting pharmaceutical compositions and to novel compounds disclosed herein.
  • the present invention relates to the inhibition of endothelin converting enzyme using a thiol derivative of formula I - 2 -
  • R represents bicyclic carbocyclic aryl or bicyclic heterocyclic aryl; or a wholly or partially saturated form thereof; or
  • R represents monocyclic carbocyclic aryl substituted by carbocyclic aryl or by heterocyclic aryl;
  • R represents monocyclic carbocyclic aryl substituted by cycloalkyl
  • R represents monocyclic carbocyclic aryl substituted by azacycloalkyl which is optionally substituted by lower alkyl or acyl;
  • R represents cycloalkyl substituted by cycloalkyl or azacycloalkyl
  • Rj represents hydrogen or acyl
  • R 2 represents hydrogen, lower alkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, biaryl, biaryl-lower alkyl,
  • R 3 represents hydrogen or lower alkyl; or R 2 and R 3 together with the carbon atom to which they are attached represent cycloalkylidene or benzo-fused cycloalkylidene;
  • a together with the carbon atom to which it is attached forms a ring and represents 3 to 10 membered cycloalkylidene or 5 to 10 membered cycloalkenylidene radical which may be substituted by lower alkyl or aryl-lower alkyl or may be fused to a saturated or unsaturated carbocyclic 5-7-membered ring; or A together with the carbon to which it is attached represents 5 to 6 membered oxacycloalkylidene, thiacycloalkylidene or azacycloalkylidene optionally substituted by lower alkyl, acyl or aryl-lower alkyl; or A together with the carbon atom to which it is attached represents 2,2-norbonylidene; m is zero or 1 -3;
  • Y represents 5-tetrazolyl, carboxyl or carboxyl derivatized in form of a pharmaceutically acceptable ester; disulfide derivatives derived from said compounds wherein Rj is hydrogen; or a pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for preparation of said compounds; intermediates; and methods of treating disorders in mammals which are responsive to ECE inhibition by administration of said compounds to mammals in need of such treatment.
  • esters are preferably prodrug ester derivatives, such being convertible by solvolysis or under physiological conditions to the free carboxylic acids of formula I.
  • prodrug derivatives of compounds of the invention having a free carboxyl, sulfhydryl or hydroxyl group, said prodrug derivatives being convertible by solvolysis or under physiological conditions to the free carboxyl, sulfhydryl and/or hydroxyl compounds.
  • Prodrug derivatives are e.g. the esters of free carboxylic acids and S-acyl and O-acyl derivatives of thiols, or alcohols, wherein acyl has meaning as defined herein.
  • prodrug esters of carboxylic acids are preferably e.g. lower alkyl esters, cycloalkyl esters, lower alkenyl esters, aryl-lower alkyl esters, ⁇ -(lower alkanoyloxy)-lower alkyl esters such as the pivaloyloxy-methyl ester, and ⁇ -(lower alkoxycarbonyl- or di-lower alkylamino carbonyl-)-lower alkyl esters.
  • Pharmaceutically acceptable salts are salts derived from pharmaceutically acceptable bases for any acidic compounds of the invention, e.g. those wherein Y represents carboxyl.
  • Such are e.g. alkali metal salts (e.g. sodium, potassium salts), alkaline earth metal salts (e.g. magnesium, calcium salts), amine salts (e.g. tromethamine salts).
  • Preferred as endothelin converting enzyme inhibitors are the compounds with the S- configuration of formula II R
  • R represents benzothiophenyl, naphthyl, benzofuranyl, indolyl, or monocyclic carbocyclic aryl substituted by monocyclic carbocyclic aryl or by monocyclic heterocyclic aryl;
  • Ri represents hydrogen or carboxyl derived acyl;
  • R 2 represents lower alkyl, hydroxy-lower alkyl, (lower alkylthio- or lower alkoxy-)lower alkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, or biaryl-lower alkyl;
  • Y represents 5-tetrazolyl, carboxyl or carboxyl derivatized in form of a pharmaceutically acceptable ester;
  • n represents 2-6, preferably 2, 4 or 5; disulfide derivatives derived from said compounds wherein R « is hydrogen; or a pharmaceutically
  • R ⁇ represents hydrogen, aryl-lower alkanoyl, lower alkanoyl, lower alkoxy-lower alkanoyl, or heterocyclic or carbocyclic aroyl
  • R 2 represents C 2 -C 4 alkyl interrupted by S or O, C 2 -C 5 -alkyl or cyclohexyl
  • Y represents 5-tetrazolyl, carboxyl, lower alkoxycarbonyl, carbocyclic or heterocyclic aryl-lower alkoxycarbonyl, ⁇ -(lower alkanoyloxy-, lower alkoxycarbonyl- or di- lower alkylaminocarbonyl-)lower alkoxycarbonyl
  • n is 2, 4 or 5; or a pharmaceutically acceptable salt thereof.
  • R represents benzothiophenyl, naphthyl, benzofuranyl, indolyl, or monocyclic carbocyclic aryl substituted by monocyclic carbocyclic aryl or by monocyclic heterocyclic aryl;
  • R t represents hydrogen, lower alkanoyl, methoxy-lower alkanoyl, benzoyl or pyridylcarbonyl;
  • R 2 represents C 2 -C 5 -alkyl, cyclohexyl or C 2 -C 4 -alkyl interrupted by O or S;
  • Y represents 5-tetrazolyl, carboxyl, lower alkoxycarbonyl, benzyloxycarbonyl, pyridylmethoxycarbonyl, ⁇ -(lower alkanoyloxy-, lower alkoxycarbonyl- or di-lower alkylaminocarbonyl-) lower alkoxycarbonyl; or a pharmaceutically acceptable salt thereof.
  • R represents benzothiophenyl, naphthyl, benzofuranyl, indolyl or monocarbocyclic aryl substituted by monocyclic carbocyclic aryl or by monocyclic heterocyclic aryl;
  • W represents CH 2 , O, S or NR in which R 4 is hydrogen, acyl, lower alkyl or aryl-lower alkyl;
  • Ri represents hydrogen, lower alkanoyl, methoxy-lower alkanoyl, benzoyl or pyridylcarbonyl;
  • R 2 represents C 2 -C 5 -alkyl, cyclohexyl or C 2 -C 4 -alkyl interrupted by O or S; - 6 -
  • Y represents 5-tetrazolyl, carboxyl, lower alkoxycarbonyl, benzyloxycarbonyl, pyridylmethoxycarbonyl, ⁇ -(lower alkanoyloxy-, lower alkoxycarbonyl- or di-lower alkylaminocarbonyl-) lower alkoxycarbonyl; or a pharmaceutically acceptable salt thereof.
  • R represents 4-biphenylyl or 3-indolyl;
  • R « represents hydrogen or lower alkanoyl;
  • R 2 represents C 3 -C 5 - alkyl,
  • Y represents 5-tetrazolyl, carboxyl, lower alkoxycarbonyl, benzyloxycarbonyl, pyridylmethoxycarbonyl, ⁇ -(lower alkanoyloxy-, lower alkoxycarbonyl- or di-lower alkylaminocarbonyl-) lower alkoxycarbonyl; or a pharmaceutically acceptable salt thereof.
  • a particular preferred embodiment relates to compounds of any of the above formulae wherein R represents 4-biphenylyl; R ⁇ is hydrogen or lower alkanoyl; R 2 is n-propyl, n-butyl or isobutyl; and Y is 5-tetrazolyl or particularly preferred carboxyl or lower alkoxycarbonyl; or a pharmaceutically acceptable salt thereof.
  • a particular aspect of the invention is directed to the novel compounds of formulae I, II, III, Ilia and lllb wherein
  • R represents monocyclic carbocyclic aryl substituted by cycloalkyl
  • R represents monocyclic carbocyclic aryl substituted by azacycloalkyl optionally substituted on nitrogen by lower alkyl or acyl;
  • R represents cycloalkyl substituted by cycloalkyl; and the other symbols have meaning as defined herein.
  • Another aspect of the invention is directed to the novel compounds of formulae I, II, III, Ilia and lllb wherein Y represents 5-tetrazolyl and the other symbols have meaning as defined herein.
  • Preferred compounds of the invention include the novel compounds of formulae III or lllb wherein Y represents carboxy or lower alkoxycarbonyl; R ⁇ represents hydrogen or lower alkanoyl; R 2 represents lower alkyl, lower alkyl substituted by hydroxy, mercapto, phenyl, phenyl substituted by lower alkyl, lower alkoxy, hydroxy, lower alkylthio, halogen, - 7 -
  • R represents 3-indolyl, 4- (5-isoxazolyl)-phenyl, 4-(2- or 3-pyrrolyl)phenyl, 4-(2- or 3-furanyl)phenyl, 4-(2- or 3- thienyl)phenyl, 4-(2- or 3-pyridyl)-phenyl, piperidin-3-yl-phenyl which is N-unsubstituted or N- substituted by lower alkanoyl, or represents 4-(5-pyrimidinyl)-phenyi, naphthyl, 5,6,7,8- tetrahydro-naphthalen-1 -yl, 5,6,7,8-tetryhydro
  • Preferred endothelin converting enzyme inhibiting compounds of the invention include alternatively the novel compounds of formula III wherein Y represents 5-tetrazolyl, carboxyl or lower alkoxycarbonyl; R ⁇ represents hydrogen or lower alkanoyl; R 2 represents n-propyl, n-butyl, isobutyl, methoxyethyl or methylthioethyl; and R represents 3-indolyl, 4-(5- isoxazolyl)-phenyl, 4-(2- or 3-furanyl)phenyl, 4-(2- or 3-thienyl)phenyl, 4-biphenylyl, 4-(2- or 3-pyridyl)-phenyl, 4-(5-pyrimidinyl)-phenyl, or 4-biphenylyl substituted on one or both benzene rings by lower alkyl, lower alkoxy, hydroxy, lower alkylthio, halogen or trifluoromethyl; or a pharmaceutically acceptable salt thereof.
  • Y is methoxycarbonyl, R « is acetyl, R 2 is n-propyl and R is 4-biphenylyl; and pharmaceutically acceptable salts thereof.
  • Y is carboxyl, R « is hydrogen, R 2 is isobutyl and R is 3-indolyl; and pharmaceutically acceptable salts thereof.
  • Y is methoxycarbonyl, R 2 is isobutyl and R is 3-indolyl.
  • Aryl represents carbocyclic or heterocyclic aryl, either monocyclic or bicyclic.
  • Monocyclic carbocyclic aryl represents optionally substituted phenyl, being preferably phenyl or phenyl substituted by one to three substituents, such being advantageously lower alkyl, hydroxy, lower alkoxy, acyloxy, halogen, cyano, trifluoromethyl, amino, lower alkanoylamino, lower alkyl-(thio, sulfinyl or sulfonyl), lower alkoxycarbonyl, mono- or di-lower alkylcarbamoyl, or mono- or di-lower alkylamino.
  • Bicyclic carbocyclic aryl represents 1 - or 2-naphthyl or 1 - or 2-naphthyl preferably substitued by lower alkyl, lower alkoxy or halogen.
  • Monocyclic heterocyclic aryl represents preferably optionally substituted thiazolyl, thienyl, furanyl, pyridyl, pyrimidinyl, oxazolyl, isoxazolyl, pyrrolyl, imidazolyl, or oxadiazolyl.
  • Optionally substituted furanyl represents 2- or 3-furanyl or 2- or 3-furanyl preferably substituted by lower alkyl.
  • Optionally substituted pyridyl represents 2-, 3- or 4-pyridyl or 2-, 3- or 4-pyridyl preferably substituted by lower alkyl, halogen or cyano.
  • Optionally substituted thienyl represents 2- or 3-thienyl or 2- or 3-thienyl preferably substituted by lower alkyl or hydroxy-lower alkyl.
  • Optionally substituted thiazolyl represents e.g. 4-thiazolyl, or 4-thiazolyl substituted by lower alkyl.
  • Optionally substituted pyrimidinyl represents 2-, 4- or 5-pyridridinyl or 2-, 4- or 5- pyrimidinyl preferably substituted by lower alkyl.
  • Optionally substituted oxazolyl represents 2-, 4- or 5-oxazolyl or 2-, 4- or 5-oxazolyl preferably substituted by lower alkyl.
  • Optionally substituted isoxazolyl represents 3-, 4- or 5-isoxazolyl or 3-, 4- or 5- isoxazolyl preferably substituted by lower alkyl. - 9 -
  • Optionally substituted pyrrolyl represents 1 -, 2- or 3-pyrrolyl or 1 -, 2- or 3- pyrrolyl preferably substituted by lower alkyl.
  • Optionally substituted imidazolyl represents 1 -, 2- or 4- imidazolyl or 1-, 2- or 4- imidazolyl preferably substituted by lower alkyl.
  • Optionally substituted oxadiazolyl represents 3- or 5- [1 , 2, 4] oxadiazolyl or 3- or 5- [1 , 2, 4] oxadiazolyl preferably substituted by lower alkyl.
  • Bicyclic heterocyclic aryl represents preferably benzothiophenyl, benzofuranyl, indolyl or benzothiazolyl optionally substituted by hydroxy, lower alkyl, lower alkoxy or halogen, advantageously 3-indolyl, 2-benzothiazolyl, 2-benzofuranyl or 3-benzo[b]thiophenyl.
  • Aryl in aryl-lower alkyl is preferably phenyl or phenyl substituted by one or two of lower alkyl, lower alkoxy, hydroxy, lower alkanoyloxy, halogen, trifluoromethyl, cyano, lower alkanoylamino or lower alkoxycarbonyl; also, optionally substituted naphthyl.
  • Aryl-lower alkyl is advantageously benzyl or 1- or 2-phenethyl optionally substituted on phenyl by one or two of lower alkyl, lower alkoxy, hydroxy, lower alkanoyloxy, halogen or trifluoromethyl.
  • lower referred to herein in connection with organic radicals or compounds respectively defines such with up to and including 7, preferably up toand including 4 and advantageously one or two carbon atoms. Such may be straight chain or branched.
  • a lower alkyl group preferably contains 1-4 carbon atoms and represents for example ethyl, propyl, butyl or advantageously methyl.
  • a lower alkoxy group preferably contains 1 -4 carbon atoms and represents for example methoxy, propoxy, isopropoxy or advantageously ethoxy.
  • Cycloalkyl represents a saturated cyclic hydrocarbon radical which preferably contains 5 to 7 ring carbons, preferably cyclopentyl or cyclohexyl.
  • cycloalkyl(lower) alkyl represents preferably 1 - or 2-(cyclopentyl or cyclohexyl)ethyl, 1 -, 2- or 3-(cyclopentyl or cyclohexyl)propyl, or 1-, 2-, 3- or 4-(cyclopentyl or cyclohexyl)-butyl. - 10 -
  • a lower alkoxycarbonyl group preferably contains 1 to 4 carbon atoms in the alkoxy portion and represents, for example, methoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl or advantageously ethoxycarbonyl.
  • Cycloalkylidene is 3 to 10 membered, preferably 3, 5 or 6-membered, and represents a cycloalkane linking group e.g. cyclopropylidene, cyclopentylidene, cyclohexyiidene, cycloheptylidene or cyclooctylidene, in which the two attached groups are attached to the same carbon of the cycloalkane ring.
  • a cycloalkane linking group e.g. cyclopropylidene, cyclopentylidene, cyclohexyiidene, cycloheptylidene or cyclooctylidene, in which the two attached groups are attached to the same carbon of the cycloalkane ring.
  • Cycloalkenylidene is 5 to 10 membered, prefereably 5 or 6-membered, and represents a cycloalkene linking group in which the two attached groups are attached to the same carbon atom of the cycloalkene ring.
  • Cycloalkylidene fused to a saturated carbocyclic ring represents e.g. perhydronaphthylidene.
  • Cycloalkylidene fused to an unsaturated carbocyclic ring represents e.g. 1 ,1 - or 2,2- tetralinylidene or 1 ,1- or 2,2-indanylidene.
  • Membered oxacycloalkylidene represents preferably a tetrahydrofuran or tetrahyd ropy ran linking group, e.g. tetrahydrofuranylidene or tetrahydropyranylidene, in which the two attached groups are attached to the same carbon atom of the respective rings, e.g. at the 3 or 4 position thereof.
  • Membered thiacycloalkylidene represents preferably a tetrahydrothiophene or tetrahydrothiopyran linking group in which the two attached groups are attached to the same carbon atom of the respective rings, e.g. at the 3 or 4 position thereof.
  • azacyloalkylidene represents preferably a pyrrolidine or piperidine linking groups in which the two attached groups are attached to the same carbon atom of the respective rings, e.g. at the 3 or 4 position thereof, and the nitrogen may be substituted by lower alkyl, e.g. methyl, or by aryl-lower alkyl, e.g. benzyl.
  • Halogen preferably represents fluoro or chloro, but may also be bromo or iodo. - 11 -
  • Acyl is derived from a carboxylic acid and represents preferably optionally substituted lower alkanoyl, cycloalkylcarbonyl, carbocyclic aryl-lower alkanoyl, aroyl, lower alkoxycarbonyl or aryl-lower alkoxycarbonyl, advantageously optionally substituted lower alkanoyl or aroyl.
  • Lower alkanoyl is preferably acetyl, propionyl, butanoyl, pentanoyl, or pivaloyl.
  • Optionally substituted lower alkanoyl for example represents lower alkanoyl or lower alkanoyl substituted by lower alkoxycarbonyl, lower alkanoyloxy, lower alkanoylthio, lower alkoxy, or by lower alkylthio; also lower alkanoyl substituted by e.g. hydroxy, di-lower alkylamino, lower alkanoylamino, morpholino, piperidino, pyrrolidino or 1 -lower alkylpiperazino.
  • Aroyl is carbocyclic or heterocyclic aroyl, preferably monocyclic carbocyclic or monocyclic heterocyclic aroyl.
  • Monocyclic carbocyclic aroyl is preferably benzoyl or benzoyl substituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl.
  • Monocyclic carbocyclic aryl substituted by carbocyclic aryl is preferably biphenylyl, advantageously 4-biphenylyl, optionally substituted on one or both benzene rings by one or more of lower alkyl, lower alkoxy, hydroxy, lower alkylthio, halogen, trifluoromethyl, amino, acylamino or nitro.
  • Monocyclic carbocyclic aryl substituted by heterocyclic aryl is preferably phenyl, optionally substituted by lower alkyl, lower alkoxy, hydroxy, lower alkylthio, trifluoromethyl, which is substituted in the para position by monocyclic heterocyclic aryl, preferably optionally substituted thiazolyl, thienyl, furanyl, pyridyl, pyrimidinyl, oxazolyl or isoxazolyl.
  • Monocyclic heterocyclic aroyl is preferably pyridylcarbonyl or thienylcarbonyl.
  • Azacycloalkyl represents preferably piperidyl, advantageously 3-piperidyl optionally substituted on nitrogen by lower alkyl or acyl. - 12 -
  • Acyloxy is preferably optionally substituted lower alkanoyloxy, lower alkoxycarbonyloxy, monocyclic carbocyclic aroyloxy or monocyclic heterocyclic aroyloxy; also carbocyclic or heterocyclic aryl-lower alkanoyloxy.
  • Optionally substituted lower alkanoyloxy is preferably lower alkanoyloxy, such as acetyloxy, substituted by any group indicated above under optionally substituted alkanoyl.
  • Aryl-lower alkoxycarbonyl is preferably monocyclic carbocyclic-lower alkoxycarbonyl, advantageously benzyloxycarbonyl.
  • Biaryl represents for example 4-biphenylyl.
  • Biaryl-lower alkyl is preferably 4-biphenylyl-lower alkyl, advantageously 4-biphenylyl- methyl.
  • novel compounds of the invention are pharmacologically potent endothelin converting enzyme inhibitors which inhibit the formation of endothelin in mammals. They thus inhibit the biological effects of endothelin in mammals.
  • the compounds of the invention are thus particularly useful in mammals for the treatment of e.g. hypertension and heart failure, cerebrovascular disorders, e.g. cerebral vasospasm and stroke, acute and chronic renal failure, penile erectile dysfunction, pulmonary disorders e.g. bronchial asthma, and complications associated with organ transplantation.
  • cerebrovascular disorders e.g. cerebral vasospasm and stroke
  • acute and chronic renal failure e.g. cerebral vasospasm and stroke
  • penile erectile dysfunction e.g. bronchial asthma
  • complications associated with organ transplantation e.g. hypertension and heart failure
  • cerebrovascular disorders e.g. cerebral vasospasm and stroke
  • penile erectile dysfunction e.g. bronchial asthma
  • complications associated with organ transplantation e.g. hypertension and heart failure
  • cerebrovascular disorders e.g. cerebral vasospasm and stroke
  • penile erectile dysfunction e.g. bronchi
  • the above-cited properties are demonstrable in vitro and in vivo tests, using advantageously mammals, e.g. mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • Said compounds can be applied in vitro in the form of solutions, e.g. preferably aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g. as a suspension or in aqueous solution.
  • the dosage in vitro may range between about 10 "5 molar and 10 "9 molar concentrations.
  • the dosage in vivo may range depending on the route of administration, between about 0.1 and 50 mg/kg, advantageously between about 1.0 and 25 mg/kg.
  • the in vitro inhibition of endothelin-converting enzyme can be determined as follows: - 13 -
  • test compound is dissolved in dimethyl sulfoxide or 0.25 M sodium bicarbonate solution, and the solution is diluted with a pH 7.4 buffer to the desired concentration.
  • Endothelin converting enzyme is partially purified from porcine primary aortic endothelial cells by DE52 anion exchange column chromatrography and its activity is quantified by radioimmunoassay as described in Anal. Biochem. 212, 434-436 (1993).
  • the native enzyme can be substituted by a recombinant form of ECE, as described, for example in Cell 78, 473-485 (1994).
  • Human ECE-1 has been described by several groups (Schmidt, M. et al. FEBS Letters, 1994, 356, 238-243; Kaw, S.; Emoto, N.; Jeng, A.; Yanagisawa, M. 4th Int. Conf.
  • ECE inhibiton can be determined as described in Biochem. Mol. Biol. Int. 31, (5), 861 -867 (1993), by radioimmunoassay to measure ET-1 formed from big ET-1.
  • recombinant human ECE-1 (rhECE-1 ) can be used, as follows:
  • rhECE-1 Chinese hamster ovary cells expressing recombinant human endothelin converting enzyme-1 (rhECE-1 ; Kaw, S.; Emoto, N.; Jeng, A.; Yanagisawa, M. 4th Int. Conf. on Endothelin; April 23-25, London (UK), 1995; C6) are cultured in DMEM/F12 medium containing 10% fetal bovine serum and 1x antibiotic-antimycotic.
  • Cells are harvested by scraping, pelleted by centrifugation, and homogenized at 4 °C in a buffer containing 5 mM MgCI 2 , 1 ⁇ M pepstatin A, 100 ⁇ M leupeptin, 1 mM PMSF, and 20 mM Tris, pH 7.0, with a ratio of 2 mL of buffer/mL of cells.
  • the cell debris is removed by brief centrifugation, and the supernatant is centrifuged again at 100,000 x g for 30 minutes.
  • the resulting pellet is resuspended in a buffer containing 200 mM NaCI and 50 mM Tes, pH 7.0, at a protein concentration about 15 mg/mL and stored in aliquots at -80°C.
  • a concentration-response curve of each inhibitor is determined.
  • An IBM-compatible version of ALLFIT program is used to fit data to a one-site model.
  • the compound of Example 5j demonstrates an IC 50 of about 11 nM in the in vitro assay for rh-ECE-1 inhibition.
  • Endothelin converting enzyme inhibition can also be determined in vivo by measuring the inhibition of big ET-1 -induced pressor response in the anesthesized or conscious rat, as described below.
  • the effect of the inhibitors on the pressor response resulting from big ET- 1 challenge is measured in Sprague-Dawley rats as described in Biochem. Mol. Biol. Int. 31_, (5), 861 -867 (1993). Results are expressed as percent inhibition of the big ET-1 -induced pressor response as compared to vehicle.
  • mice Male Sprague-Dawley rats are anesthetized with Inactin (100 mg/kg i.p.) and instrumented with catheters in the femoral artery and vein to record mean arterial pressure (MAP) and administer compounds, respectively.
  • MAP mean arterial pressure
  • a tracheostomy is performed and a cannula inserted into the trachea to ensure airway patency.
  • the body temperature of the animals is maintained at 37 ⁇ 1 °C by means of a heating blanket.
  • MAP is allowed to stabilize before interrupting autonomic neurotransmission with chlorisondamine (3 mg/kg i.v.).
  • Rats are then treated with the test compound at 10 mg/kg i.v. or vehicle and challenged with big ET-1 (1 nmol/kg i.v.) 15 min and 90 min later.
  • big ET-1 (1 nmol/kg i.v.
  • mice Male Sprague-Dawley rats are anesthetized with methohexital sodium (75 mg/kg i.p.) and instrumented with catheters in the femoral artery and vein to measure mean arterial pressure (MAP) and administer drugs, respectively.
  • the catheters are threaded through a swivel system that enables the rats to move freely after regaining consciousness.
  • the rats are allowed to recover from this procedure for 24 h before initiating the study.
  • MAP is recorded via the femoral artery catheter and a test compound or vehicle is adminstered via the femoral vein. Animals are challenged with big ET-1 at 1 nmol/kg i.v. at various times after dosing.
  • animals can be re-tested at another dose of test compound or vehicle.
  • the data are reported as the change in MAP produced by big ET-1 at 2- minute intervals in animals treated with the test compound as compared to vehicle.
  • ECE inhibition can also be determined in vivo by measuring the inhibition of the big ET-1 induced pressor response in conscious spontaneously hypertensive rats (SHR), e.g. as described in Biochem. Biophys. Res. Commun. 204, 407-412 (1994).
  • SHR conscious spontaneously hypertensive rats
  • the compounds of the invention inhibit cerebrovascular constriction and are useful for the treatment and alleviation of cerebral spasm. They are thus in turn useful for the treatment and alleviation of conditions in which cerebral vasospasm occurs. Such conditions include stroke, cerebral ischemia, acute and traumatic brain injury, brain hemorrhage, in particular aneurysmal subarachnoid hemorrhage, as well as migraine. - 16 -
  • Bronchial effects can be determined by measuring the effect in a model of ET-1 induced bronchoconstriction.
  • Compounds of the invention may also possess angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitory activity. Tests for determination thereof are described e.g. in U.S. patent 5,506,244 which is incorporated herein by reference.
  • ACE angiotensin converting enzyme
  • NEP neutral endopeptidase
  • the combined effect is beneficial for e.g. the treatment of cardiovascular disorders in mammals such as hypertension, congestive heart failure and renal failure.
  • the compounds of the invention can generally be prepared according to methodology described in U.S. Patent 5,506,244, in particular using the processes described and illustrated below, e.g.
  • R, m, X and Y' have meaning as defined above;
  • R ⁇ ' represents a labile S-protecting group, e.g. acyl, t-butyl or optionally substituted benzyl; and converting a resulting product wherein R «' is optionally substituted benzyl to a compound of formula I wherein R ⁇ is hydrogen; and in above said process, if temporarily protecting any interfering reactive group(s), removing said protecting group(s), and then isolating the resulting compound of the invention; and, if desired, converting any resulting compound of the invention into another compound of the invention; and/or, if desired, - 18 -
  • thiol, carboxyl, amino and hydroxyl groups are optionally protected by conventional protecting groups that are common in preparative organic chemistry.
  • Protected thiol, carboxyl, amino and hydroxyl groups are those that can be converted under mild conditions into free thiol, carboxyl, amino and hydroxyl groups without other undesired side reactions taking place.
  • protecting groups are to protect the functional groups from undesired reactions with reaction components and under the conditions used for carrying out a desired chemical transformation.
  • the need and choice of protecting groups for a particular reaction is known to those skilled in the art and depends on the nature of the functional group to be protected (thiol, carboxyl, amino group, etc.), the structure and stability of the molecule of which the substituent is a part, and the reaction conditions.
  • Suitable protecting groups for the preparation of the 5-tetrazolyl compounds are the protecting groups customarily used in tetrazole chemistry, especially triphenylmethyl, unsubstituted or substituted, (for example nitro-substituted), benzyl such as 4-nitrobenzyl, lower alkoxymethyl such as methoxy- and ethoxymethyl, also 1 -ethoxyethyl, lower alkylthiomethyl such as methylthiomethyl, silyl such as tri-lower alkylsilyl, for example - 19 -
  • the removal of the protecting groups is carried out in accordance with known methods.
  • the triphenylmethyl group is customarily removed by hydrolysis, especially in the presence of an acid, or by hydrogenolysis in the presence of a hydrogenation catalyst; 4-nitrobenzyl is removed, for example, by hydrogenolysis in the presence of a hydrogenation catalyst; methoxy- or ethoxy-methyl is removed, for example, by treatment with a tri-lower alkyl-, such as triethyl- or tributyl-tin bromide; methylthiomethyl is removed, for example, by treatment with trifluoroacetic acid; silyl radicals are removed, for example, by treatment with fluorides, such as tetra-lower alkyl-ammonium fluorides, for example tetrabutylammonium fluoride, or alkali metal fluorides, for example sodium fluoride; 2-cyanoethyl is removed, for example, by hydrolysis, for example with sodium hydroxide solution; 2-me
  • a tetrazole protecting group which is preferably introduced by conversion of a similarly protected amide to the corresponding N-substituted tetrazole, is e.g. cyanoethyl, p- nitrophenylethyl, lower alkoxycarbonylethyl, phenylsulfonylethyl and the like.
  • Such tetrazole protecting groups can be removed by a retro-Michael deblocking reaction with a base such as DBN (1 ,5-diazabicyclo[4.3.0]non-5-ene), an amidine, an alkali metal carbonate or alkoxide, e.g. potassium carbonate, potassium t-butoxide, sodium methoxide in an inert solvent.
  • An amino protecting group is preferably t-butoxycarbonyl or benzyloxycarbonyl.
  • a sulfhydryl protecting group is preferably lower alkanoyl, e.g. acetyl.
  • the condensation according to process (a) of a compound of formula IV with a free carboxylic acid of formula V is carried out advantageously in the presence of a condensing agent such as dicyclohexylcarbodiimide or N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide, and hydroxybenzotriazole, 1 -hydroxy-7-azabenzotriazole, chlorodimethoxytriazine or benzotriazol-1 -yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP Reagent), and triethylamine or N-methylmorpholine, in an inert polar solvent such as dimethylformamide or methylene chloride, preferably at room temperature.
  • a condensing agent such as dicyclohexylcarbodiimide or N-(3-dimethylaminopropyl)-N'-ethylcarbodi
  • condensation of a compound of formula IV with a reactive functional derivative of an acid of formula V in the form of an acid halide, advantageously an acid chloride, or mixed anhydride is carried out in an inert solvent such as toluene or methylene chloride, advantageously in the presence of a base, e.g. an inorganic base such as potassium carbonate or an organic base such as triethylamine, N-methylmorpholine or pyridine, preferably at room temperature.
  • a base e.g. an inorganic base such as potassium carbonate or an organic base such as triethylamine, N-methylmorpholine or pyridine, preferably at room temperature.
  • Reactive functional derivatives of carboxylic acids of formula V are preferably acid halides (e.g. the acid chloride) and mixed anhydrides, such as the pivaloyl or isobutyloxycarbonyl anhydride, or activated esters such as benzotriazole, 7- azabenzotriazole or hexafluorophenyl ester.
  • acid halides e.g. the acid chloride
  • mixed anhydrides such as the pivaloyl or isobutyloxycarbonyl anhydride
  • activated esters such as benzotriazole, 7- azabenzotriazole or hexafluorophenyl ester.
  • the starting materials of formula IV can be prepared according to methods described herein and illustrated in the examples.
  • R 5 is a labile amino protecting group, e.g. t-butoxycarbonyl, to obtain the corresponding N-protected compound of formula IV.
  • the condensation of a compound of formula X with a compound of formula XI is carried out by methodology well known in peptide synthesis, e.g. as described above for the condensation of a compound of formula IV with a compound of formula V.
  • the N-protecting group is removed according to methods well-known in the art, e.g. the t-butoxycarbonyl is removed with anhydrous acid such as trifluoroacetic acid.
  • the starting amino acids and esters of compounds of formula X and XI are either known in the art or if new can be prepared according to methods well-known in the art, e.g. from the corresponding aldehyde or ketone.
  • the ⁇ -amino acids of formula X are preferably obtained as the -S- enantiomers.
  • Resolution of N-acyl amino acid esters can be performed by hydrolysis with an esterase, e.g. alcalase, to give the S-amino acid.
  • the starting materials of formula V are known or if new may be prepared according to conventional methods.
  • the starting materials are prepared e.g. from the corresponding racemic or optically active ⁇ -amino acids, by conversion thereof to the ⁇ -bromo derivative followed by displacement thereof with the appropriate thio acids or optionally substituted benzylthiol, under basic conditions, for example as illustrated in European Patent application No. 524,553 published January 27, 1993.
  • S-Debenzylation of the resulting final products is carried out by reductive cleavage, e.g. with sodium in ammonia.
  • S-Deacylation is carried out by e.g. base catalyzed hydrolysis with dilute aqueous sodium hydroxide or lithium hydroxide.
  • a reactive esterified hydroxyl group, represented by Z, is a hydroxyl group esterified by a strong inorganic or organic acid.
  • Corresponding Z groups are in particular halo, for example chloro, bromo or iodo, also sulfonyloxy groups, such as lower alkyl- or arylsulfonyloxy groups, for example (methane-, ethane-, benzene- or toluene-) sulfonyloxy groups, also the trifluoromethylsulfonyloxy group.
  • the displacement is carried out in an inert solvent, such as dimethylformamide, methylene chloride or THF in the presence of a base such as potassium carbonate, triethylamine, diisopropylethylamine, N-methylmorpholine, and the like at room or elevated temperatures.
  • an inert solvent such as dimethylformamide, methylene chloride or THF
  • a base such as potassium carbonate, triethylamine, diisopropylethylamine, N-methylmorpholine, and the like at room or elevated temperatures.
  • the starting materials of formula VIII can be prepared by reacting the amide derivative of formula IV with an acid of the formula
  • R 2 and R 3 and Z have meaning as defined above, under conditions described for process (a).
  • Acids of formula XII e.g. wherein Z is bromo, can be prepared from the corresponding ⁇ -aminoacids according to methods well known in the art.
  • active acids of formula XII can be obtained from optically active ⁇ -aminoacids as illustrated herein.
  • R is biaryl
  • e.g. ⁇ /-Boc-cycloleucyl-biarylalanine derivatives 7 are prepared from the Suzuki coupling reactions of e.g. 2-[(1 -tert- butoxycarbonylamino-cyclopentanecarbonyl)-amino]-3-(4- trifluoromethanesulfonyloxyphenyl)-propionic acid ethyl ester 14 and various arylboronic acids according to a modification of the method reported by Carlson and Shieh (J. Org. Chem. 1992, 57, 379) using PdCl2(dppf) as the catalyst, K3PO4 as base, and DME or THF as solvent. The synthesis of the final products is then completed as in Sequence A. 24
  • the biaryl substituted intermediates 7 may also be obtained by coupling the iodophenyl substituted intermediate 19 with various arylstannates under the conditions of a palladium catalyzed Stille coupling reaction using toluene or dioxane as solvent.
  • R p is a tetrazolyl protecting group (such as 2-cyanoethyl).
  • the tetrazole starting materials of formula X' are prepared from the corresponding N- acyl amino acids by first converting such to the N-R p -substituted amides. The resulting - 27 -
  • amides are then treated under conditions known in the art for tetrazole ring formation, e.g. under conditions described in Tetrahedron Letters 1979. 491 and J. Org. Chem. 56, 2395 (1991 ), e.g. with trimethylsilyl azide in the presence of diisopropyl azodicarboxylate and triphenylphosphine. Removal of the N- acyl group leads to the starting materials of formula X'.
  • the tetrazole protecting group is preferably removed after formation of the bromo intermediate and prior to reaction with e.g. potassium thioacetate.
  • the free mercaptans may be converted to the S-acyl derivatives by reaction with a reactive derivative of a carboxylic acid (corresponding to R « being acyl in formula I), such as an acid anhydride or said chloride, preferably in the presence of cobalt chloride (CoCI 2 ) in an inert solvent such as acetonitrile or methylene chloride.
  • a reactive derivative of a carboxylic acid such as an acid anhydride or said chloride
  • CoCI 2 cobalt chloride
  • an inert solvent such as acetonitrile or methylene chloride.
  • the free mercaptans may be oxidized to the corresponding disulfides, e.g. by air oxidation or with the use of mild oxidizing agents such as iodine in alcoholic solution. Conversely, disulfides may be reduced to the corresponding mercaptans, e.g. with reducing agents such as sodium borohydride, zinc and acetic acid or tributylphosphine.
  • Carboxylic acid esters may be prepared from a carboxylic acid by condensation with e.g. the halide corresponding to the esterifying alcohol in the presence of a base, or with an excess of the alcohol, in the presence of an acid catalyst, according to methods well-known in the art.
  • Carboxylic acid esters and S-acyl derivatives may be hydrolyzed, e.g. with aqueous alkali such as alkali metal carbonates or hydroxides. - 28 -
  • Carbocyclic or heterocyclic aromatic compounds or intermediates may be reduced to the corresponding alicyclic compounds or interemediates according to methods illustrated herein, e.g. by catalytic hydrogenation.
  • stereoisomers e.g. diastereomers
  • these can be separated by known procedures such as fractional crystallization and chromatography (e.g. thin layer, column, flash chromatography).
  • Racemic free acids can be resolved into the optical antipodes by fractional crystallization of d- or I- ( ⁇ -methylbenzylamine, cinchonidine, cinchonine, quinine, quinidine, dehydroabietylamine, brucine or strychnine) salts and the like.
  • Racemic products if not diastereoisomers, can first be converted to diastereoisomers with optically active reagents (such as optically active alcohols to form esters) which can then be separated as described above, and e.g. hydrolyzed to the individual enantiomer.
  • Racemic products can also be resolved by chiral chromatography, e.g. high pressure liquid chromatography using a chiral adsorbent; also by enzymatic resolution, e.g. of esters with alcalase.
  • diluents preferably such as are inert to the reagents and are solvents thereof, of catalysts, alkaline or acidic condensing or said other agents respectively and/or inert atmospheres, at low temperatures, room temperature or elevated temperatures, preferably near the boiling point of the solvents used, at atmospheric or superatmospheric pressure.
  • the invention further includes any variant of said processes, in which an intermediate product obtainable at any stage of the process is used as a starting material and any remaining steps are carried out, or the process is discontinued at any stage thereof, or in which the starting materials are formed under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure antipodes. Mainly those starting materials should be used in said reactions, that lead to the formation of those compounds indicated above as being preferred.
  • the present invention additionally relates to the use in mammals of the compounds of the invention and their pharmaceutically acceptable, non-toxic acid addition salts, or pharmaceutical compositions thereof, as medicaments, for inhibiting endothelin converting - 29 -
  • endothelin dependent disorders such as those mentioned hereinabove, e.g. cardiovascular disorders such as hypertension, heart-failure, acute and chronic renal failure, stroke and cerebral vasospasm, as well as bronchial asthma, erectile dysfunction, and complications associated with organ transplantation.
  • cardiovascular disorders such as hypertension, heart-failure, acute and chronic renal failure, stroke and cerebral vasospasm, as well as bronchial asthma, erectile dysfunction, and complications associated with organ transplantation.
  • the present invention also relates to the use of the compounds of the invention for the preparation of pharmaceutical compositions, especially pharmaceutical compositions having endothelin converting enzyme inhibiting activity.
  • compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal and parenteral administration to mammals, including man, for the treatment of endothelin dependent disorders, comprising an effective amount of a pharmacologically active compound of the invention or a pharmaceutically acceptable salt thereof, alone or in combination with one or more pharmaceutically acceptable carriers.
  • the pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application.
  • Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salts and/or polyethyleneglycol; for tablets also c) binders, e.g.
  • Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
  • compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
  • adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
  • the compositions may also contain other therapeutically valuable substances.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient. - 30 -
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound, optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • a unit dosage for a mammal of about 50 to 70 kg may contain between about 5 and 100 mg of the active ingredient.
  • the dosage of active compound is dependent on the species of warm-blooded animal (mammal), the body weight, age and individual condition, and on the form of administration.
  • R and S are used to indicate the absolute configuration at each asymmetric center.
  • L-Amino acids as used herein correspond to the S-configuration.
  • the stereo chemical configuration, as assigned to the products of the examples, is indicated in a conventional manner in the respective structural formulae.
  • BOP benzotriazol -1 -yloxy-tris (dimethylamino) phosphonium hexafluorophosphate
  • HOAT is the abbreviation for 1 -hydroxy-7-azabenzotriazole
  • HOBT is the abbreviation for 1-hydroxybenzotriazole
  • EDCI is the abbreviation for 1 -ehtyl-3-(3- dimethylaminopropyl) carbodiimide
  • hydrochloride DCC is the abbreviation for dicyclohexylcarbodiimide.
  • the starting material is prepared as follows:
  • reaction mixture is then diluted with ether and washed successively three times with water, two times with 1 M hydrochloric acid, two times with saturated sodium bicarbonate, and two times with brine.
  • the etheral phase is then dried over sodium sulfate and concentrated to afford ⁇ S-bromohexanoylcycloleucyl-L-biphenylalanine methyl ester , as a light yellow solid.
  • the white solid is extracted into ethyl acetate, washed with brine, dried over sodium sulfate, and concentrated to dryness to afford an off-white solid which is further dried under high vacuum in a 50 °C oven to yield 3-biphenyl-4-yl-2- ⁇ [1 -(2R-mercapto-hexanoylamino)- cyclopentanecarbonyl]-amino ⁇ -propionic acid; mp 104-107 °C. 37
  • the starting material is prepared from ⁇ R-bromo- ⁇ S-hydroxybutanoic acid.
  • Ra ⁇ R-mercapto- ⁇ R-hydroxybutanoyl; mp 155-160 °C;
  • NBS N-bromosuccinimide
  • 2-methoxy-biphenyl-4-yl 2-methoxy-biphenyl-4-yl-methanol
  • triphenyl phosphine 2.0 g, 7.0 mmol
  • the cooling bath is removed and the reaction mixture is stirred at room temperature overnight.
  • the reaction mixture is then concentrated in vacuo, and the residue is purified by chromatography on silica gel (10% EtOAc/hexane) to furnish 4-bromomethy!-2-methoxy-biphenyl as a clear, colorless oil.
  • the 2-amino-3-(2-methoxybiphenyl-4-yl)-propionic acid methyl ester hydrochloride intermediate is prepared from 4-bromomethyl-2-methoxy-biphenyl according to the procedure reported by Williams and Im (J. Am. Chem. Soc. 1991 , 113, 9726). White solid; 1 H NMR (250 MHz, CD3OD) ⁇ 7.25-7.47 (m, 6 H), 6.96 (s, 1 H), 6.92 (d, 1 H), 4.39 (dd, 1 H), 3.86 (s, 3 H), 3.81 (s, 3 H), 3.19 (dd, 1/2 of CH2 ABX, 1 H, the other H buried under solvent peak).
  • the 4-bromomethyl-2-methoxy-biphenyl starting material is prepared as follows:
  • 3-Methoxy-4-trifluoromethanesulfonyloxybenzaldehyde is prepared from 4-hydroxy-3- methoxybenzaldehyde oil; 1 H NMR (250 MHz, CD3OD) 6 9.95 (s, 1 H), 7.55 (d, 1 H), 7.50 (dd, 1 H), 7.40 (d, 1 H), 3.97 (s, 3 H). Such is converted to 2-methoxy-biphenyl-4- carboxaldehyde according to the procedure reported in Chem. Rev.
  • 4-bromomethyl-2,2 ' -dimethoxy-biphenyl is prepared according to the procedure described above for the synthesis of 4-bromomethyl-2-methoxy-biphenyi; 1 H NMR (250 MHz, CDCI3) 6 7.35 (dt, 1 H), 7.20-7.28 (m, 2 H), 6.90-7.10 (m, 4 H), 4.53 (s, 2 H), 3.78 (s, 3 H), 3.76 (s, 3 H).
  • the starting material is prepared as follows:
  • Bisbenzoyl peroxide (560 mg, 0.232 mmol) is added to a solution of 2.17 g (13.65 mmol) of 5-(4-methyl-phenyl)-isoxazole (Lin, Y.-i.; Lang, Jr., S. A. J. Org. Chem. 1980, 45, 4857) and N-bromosuccinimide (2.43 g, 13.65 mmol) in 64 mL of CCI 4 , and the reaction mixture is heated at reflux overnight.
  • 2-Amino-3-(4-isoxazole-5-yl-phenyl)-propionic acid hydrochloride is prepared according to the procedure of Stork et al. (J. Org. Chem. 1976, 41, 3491 ) using NaHMDS as the base, from 5-(4-bromomethyl-phenyl)-isoxazole; white solid; 1 H NMR (300 MHz, CD 3 OD) ⁇ 8.43 (d, 1 H), 7.86 (d, 2H), 7.43 (d, 2 H), 6.81 (d, 1 H), 4.35 (t, 1 H), 4.25 (q, 2 H), 3.21-3.34 (m, 2 H), 1.23 (t, 3 H).
  • the starting material is prepared as follows:
  • Trifluoromethanesulfonic anhydride (7.1 mmol) is added slowly dropwise to a solution of 2-[(1 -te/ ⁇ -butoxycarbonylamino-cyclopentanecarbonyl)-amino]-3-(4-hydroxy- phenyl)-propionic acid ethyl ester (2.70 g, 6.4 mmol) and 0.7 mL (8.7 mmol) of pyridine in 20 mL of CH 2 CI 2 at 0 °C, and the solution is stirred at 0 °C for 1 hour. The reaction mixture is then partitioned between water and CH 2 CI 2 .
  • the reaction mixture is partitioned between EtOAc and water, and the aqueous phase is extracted with EtOAc. The combined organic phases are washed with brine, dried over MgSO 4 , filtered, and concentrated. The product is purified by chromatography on silica gel (30% EtOAc/Hex).
  • the starting material is prepared as follows:
  • Acetyl chloride (50 mL, 0.70 mmol) is added slowly to a solution of 2-[(1 -fert- butoxycarbonylamino-cyclopentanecarbonyl)-amino]-3-[4-(piperidin-3-yl)-phenyl]-propionic acid ethyl ester (277 mg, 0.57 mmol) and 11 mL (0.79 mmol) of Et3N in 2 mL of CH2CI2. The reaction mixture is stirred at 0 °C for 2 h, and then partitioned between saturated - 58 -
  • the aqueous phase is acidified with 40 mL of 1 N HCl, and the product is filtered off as a white solid;
  • 1 H NMR (250 MHz, CD3OD) 6 7.05 (s, 1 H), 4.15 (d 1 H), 2.15-2.35 (m, 3 H), 1.85-2.00 (m, 2 H), 1.70-1.80 (m, 4 H), 1.00 (d, 3 H), 0.95 (d, 3 H); [ ⁇ ]D +17.87 (10.38 mg/mL in MeOH).
  • 2-(Benzhydrylidene-amino)-3-[4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]- propionic acid ethyl ester is prepared via the procedure reported by Stork (J. Org. Chem. 1976, 41, 3491 ), using NaHMDS as the base, from 2-(4-bromomethyl-phenyl)-4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolane.
  • biaryl substituted amino acid ester starting materials leading to products disclosed in the following examples can be similarly prepared.
  • the starting material is prepared as follows:
  • the Boc-protected boronophenylalanine reagent 2-(N-f-Boc-amino)-3-[4-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-phenyl]propionic acid ethyl ester (see Roberts et al., Tetrahedron Letters 1980, 21 , 3435) is condensed with 1 -acetoxy-2-iodobenzene in the Suzuki coupling reaction followed by coupling to N-f-Boc-cycloleucine methyl ester to obtain the intermediate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne les composés de la formule (I) comme inhibiteurs de l'enzyme de conversion d'endothéline, les variables ayant les significations données antérieurement.
PCT/EP1999/002690 1998-04-23 1999-04-21 Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline WO1999055726A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BR9909805-9A BR9909805A (pt) 1998-04-23 1999-04-21 Certos inibidores de tiol de enzima de conversão de endotelina
EP99920729A EP1073674A1 (fr) 1998-04-23 1999-04-21 Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline
CA002323691A CA2323691A1 (fr) 1998-04-23 1999-04-21 Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline
IL13824699A IL138246A0 (en) 1998-04-23 1999-04-21 Certain thiol inhibitors of endothelin-converting enzyme
SK1581-2000A SK15812000A3 (sk) 1998-04-23 1999-04-21 Inhibítory enzýmu na premenu endotelínu
JP2000545884A JP4350306B2 (ja) 1998-04-23 1999-04-21 エンドセリン変換酵素のチオール型阻害剤
PL99343594A PL343594A1 (en) 1998-04-23 1999-04-21 Certain thiol inhibitors of endothelin-converting enzyme
KR1020007011725A KR20010034816A (ko) 1998-04-23 1999-04-21 엔도텔린-전환 효소의 특정 티올 억제제
HU0101640A HUP0101640A3 (en) 1998-04-23 1999-04-21 Certain thoil inhibitors of endothelin-converting enzyme
AU38199/99A AU3819999A (en) 1998-04-23 1999-04-21 Certain thiol inhibitors of endothelin-converting enzyme
US09/690,060 US6423727B1 (en) 1998-04-23 2000-10-16 Certain thiol inhibitors of endothelin-converting enzyme
NO20005293A NO20005293L (no) 1998-04-23 2000-10-20 Visse tiolininhibitorer av endotelinomdannende enzym
US10/080,798 US6613782B2 (en) 1998-04-23 2002-02-21 Certain thiol inhibitors of endothelin-converting enzyme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6526598A 1998-04-23 1998-04-23
US09/065,265 1998-04-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/690,060 Continuation US6423727B1 (en) 1998-04-23 2000-10-16 Certain thiol inhibitors of endothelin-converting enzyme

Publications (1)

Publication Number Publication Date
WO1999055726A1 true WO1999055726A1 (fr) 1999-11-04

Family

ID=22061502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/002690 WO1999055726A1 (fr) 1998-04-23 1999-04-21 Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline

Country Status (16)

Country Link
EP (1) EP1073674A1 (fr)
JP (1) JP4350306B2 (fr)
KR (1) KR20010034816A (fr)
CN (1) CN1297453A (fr)
AU (1) AU3819999A (fr)
BR (1) BR9909805A (fr)
CA (1) CA2323691A1 (fr)
HU (1) HUP0101640A3 (fr)
ID (1) ID26822A (fr)
IL (1) IL138246A0 (fr)
NO (1) NO20005293L (fr)
PL (1) PL343594A1 (fr)
RU (1) RU2000129510A (fr)
SK (1) SK15812000A3 (fr)
WO (1) WO1999055726A1 (fr)
ZA (1) ZA200004680B (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077095A2 (fr) * 2000-04-06 2001-10-18 Novartis Ag Composes organiques
US6423727B1 (en) 1998-04-23 2002-07-23 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
US6426354B1 (en) 1998-04-23 2002-07-30 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
WO2002092622A2 (fr) * 2001-05-15 2002-11-21 Novartis Ag Derives dipeptidiques
WO2003074478A1 (fr) * 2002-03-05 2003-09-12 Sumitomo Chemical Company, Limited Procédé de préparation de composés biaryle
WO2004056768A2 (fr) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
US6919343B2 (en) 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
US7071169B2 (en) * 2001-09-21 2006-07-04 Novartis Ag Pyrane derivatives as both ACE-and NEP-inhibitors
US7091380B2 (en) 2002-02-08 2006-08-15 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
AU2007205578B2 (en) * 2006-01-11 2012-06-28 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
EP2543368A1 (fr) 2007-12-11 2013-01-09 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1706121T3 (pl) * 2004-01-12 2009-02-27 Turski Lechoslaw Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych
JP3975226B2 (ja) 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
CN104725279B (zh) * 2015-02-12 2018-03-02 威海迪素制药有限公司 一种N‑Boc‑联苯丙氨酸衍生物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012611A1 (fr) * 1993-11-01 1995-05-11 Japat Ltd. Antagonistes de recepteur d'endotheline
EP0655461A1 (fr) * 1993-11-16 1995-05-31 Ciba-Geigy Ag Dérivés d'amino acide cycliques ayant une activité inhibante d'ACE et NEP
WO1997032874A1 (fr) * 1996-03-04 1997-09-12 Hoechst Marion Roussel Nouveaux derives soufres comportant une liaison amide, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012611A1 (fr) * 1993-11-01 1995-05-11 Japat Ltd. Antagonistes de recepteur d'endotheline
EP0655461A1 (fr) * 1993-11-16 1995-05-31 Ciba-Geigy Ag Dérivés d'amino acide cycliques ayant une activité inhibante d'ACE et NEP
WO1997032874A1 (fr) * 1996-03-04 1997-09-12 Hoechst Marion Roussel Nouveaux derives soufres comportant une liaison amide, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FINK E.A.: "Mercaptoacetyl dipeptides as orally active dual inhibitors of ACE and NEP", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 16, 1996, WASHINGTON US, pages 3158 - 3168, XP002111862 *
FINK E.A.: "New alpha-thiol dipeptide dual inhibitors of ACE and NEP EC 3.4.24.11", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 26, 1995, WASHINGTON US, pages 5023 - 5030, XP002111861 *
KUKKOLA P J ET AL: "DIFFERENTIAL STRUCTURE-ACTIVITY RELATIONSHIPS OF PHOSPHORAMIDON ANALOGUES FOR INHIBITION OF THREE METALLOPROTEASES: ENDOTHELIN- CONVERTING ENZYME, NEUTRAL ENDOPEPTIDASE, AND ANGIOTENSIN- CONVERTING ENZYME", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 26, no. SUPPL. 03, 1 January 1995 (1995-01-01), pages 565 - 568, XP000647537, ISSN: 0160-2446 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423727B1 (en) 1998-04-23 2002-07-23 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
US6426354B1 (en) 1998-04-23 2002-07-30 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
US6613782B2 (en) 1998-04-23 2003-09-02 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
US6689801B2 (en) 1998-04-23 2004-02-10 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
WO2001077095A2 (fr) * 2000-04-06 2001-10-18 Novartis Ag Composes organiques
WO2001077095A3 (fr) * 2000-04-06 2002-06-27 Novartis Ag Composes organiques
WO2002092622A2 (fr) * 2001-05-15 2002-11-21 Novartis Ag Derives dipeptidiques
WO2002092622A3 (fr) * 2001-05-15 2003-04-10 Novartis Ag Derives dipeptidiques
EP2239268A1 (fr) 2001-05-15 2010-10-13 Novartis AG Dérivés de dipeptide
US6992105B2 (en) 2001-05-15 2006-01-31 Novartis Ag Dipeptide derivatives
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US7071169B2 (en) * 2001-09-21 2006-07-04 Novartis Ag Pyrane derivatives as both ACE-and NEP-inhibitors
US6919343B2 (en) 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
US7091380B2 (en) 2002-02-08 2006-08-15 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
US7271280B2 (en) 2002-03-05 2007-09-18 Sumitomo Chemical Company, Limited Process for preparing a biaryl compound
US7714157B2 (en) 2002-03-05 2010-05-11 Sumitomo Chemical Company, Limited Process for preparing a biaryl compound
WO2003074478A1 (fr) * 2002-03-05 2003-09-12 Sumitomo Chemical Company, Limited Procédé de préparation de composés biaryle
WO2004056768A3 (fr) * 2002-12-20 2004-08-05 Bayer Healthcare Ag Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
WO2004056768A2 (fr) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7410962B2 (en) 2003-09-26 2008-08-12 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
AU2007205578B2 (en) * 2006-01-11 2012-06-28 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
EP2543368A1 (fr) 2007-12-11 2013-01-09 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage

Also Published As

Publication number Publication date
ID26822A (id) 2001-02-15
CA2323691A1 (fr) 1999-11-04
NO20005293L (no) 2000-12-18
IL138246A0 (en) 2001-10-31
NO20005293D0 (no) 2000-10-20
PL343594A1 (en) 2001-08-27
ZA200004680B (en) 2001-04-25
BR9909805A (pt) 2000-12-26
SK15812000A3 (sk) 2001-03-12
JP2002513032A (ja) 2002-05-08
RU2000129510A (ru) 2002-11-10
HUP0101640A3 (en) 2002-10-28
CN1297453A (zh) 2001-05-30
EP1073674A1 (fr) 2001-02-07
JP4350306B2 (ja) 2009-10-21
AU3819999A (en) 1999-11-16
KR20010034816A (ko) 2001-04-25
HUP0101640A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
KR100908152B1 (ko) 바소펩티다제 억제제로서 ｎ-말단 2-티오아실기를 갖는디펩티드 유도체
EP1073674A1 (fr) Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline
AU2002314067A1 (en) Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
EP1080104B1 (fr) Certains inhibiteurs thiol heteroaryle substitues d'une enzyme de conversion d'endotheline
US5508266A (en) Gem-disubstituted amino acid derivatives
JP3647914B2 (ja) 環式アミノ酸誘導体
HU211266A9 (en) New peptide compound and a process for the preparation thereof
US5432186A (en) Cyclic amino acid derivatives
US6613782B2 (en) Certain thiol inhibitors of endothelin-converting enzyme
JP4263095B2 (ja) Ａｃｅおよびｎｅｐの両阻害剤としてのピラン誘導体
US6689801B2 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
WO2001077095A2 (fr) Composes organiques
ZA200308590B (en) Dipeptide derivatives having a n-terminal 2-thiocyl group as vasopeptidase inhibitors.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805180.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999920729

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 38199/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 138246

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000/04680

Country of ref document: ZA

Ref document number: 200004680

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2323691

Country of ref document: CA

Ref document number: 2323691

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 507039

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09690060

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 15812000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020007011725

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999920729

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007011725

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1020007011725

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999920729

Country of ref document: EP